Press Release
Psychiatrists, Psychologists, Researchers, Investors and Media to Gather in Melbourne for Landmark Mental Health Conference
Melbourne, Victoria Jun 16, 2026 (Issuewire.com) – At a time when Australia is attracting unprecedented international attention for its leadership in psychedelic-assisted therapies, the inaugural International Psychedelic Roundtable Symposium will bring together psychiatrists, psychologists, clinicians, researchers, healthcare executives, investors, media representatives and industry leaders from Australia and overseas in Melbourne on 20 March 2027.
The one day symposium is being developed as a high level professional forum focused on the future of mental healthcare, psychiatry, psychology, neuroscience, psychedelic-assisted therapies and emerging healthcare innovation.
As global interest in psychedelic medicine continues to accelerate, Australia has emerged as one of the world’s most closely watched jurisdictions following the Therapeutic Goods Administration’s decision to permit authorised psychiatrists to prescribe MDMA and psilocybin for specific psychiatric conditions under tightly controlled circumstances.
The result has been growing international interest from clinicians, researchers, universities, healthcare providers, biotechnology companies, investors and policymakers seeking to better understand how these therapies may be integrated into modern healthcare systems.
Against this backdrop, Melbourne will host what organisers hope will become a flagship annual gathering for the Asia-Pacific region, bringing together leading voices from psychiatry, psychology, research, healthcare, investment, media and industry.
The symposium will provide an international platform for evidence-based discussion surrounding psychiatry, psychology, neuroscience, mental health innovation, clinical research, healthcare policy, workforce development, regulation, patient access, investment trends, commercialisation and the future of psychedelic-assisted therapies.
Delegates are expected from across Australia, New Zealand, North America, Europe and the broader Asia-Pacific region, with organisers targeting attendance of approximately 150 to 200 delegates for the inaugural event.
The conference will feature keynote presentations, expert panel discussions and networking opportunities designed to connect psychiatrists, psychologists, researchers, healthcare leaders, investors, founders, policymakers and media professionals operating at the forefront of this rapidly evolving sector.
In addition to scientific and clinical discussions, the symposium will explore investment, entrepreneurship, public markets, healthcare innovation, emerging companies and the growing role of specialist media in shaping awareness and understanding of psychedelic medicine globally.
Organisers for the Psychedelic Roundtable Symposium, said “The event is designed to encourage meaningful dialogue between disciplines that will ultimately play a role in shaping the future of mental healthcare.”
“We believe Melbourne has the opportunity to become the leading Asia Pacific meeting point for psychiatrists, psychologists, researchers, investors and healthcare innovators working in psychedelic medicine and mental health innovation,”
“The conversations taking place today will help shape how these therapies are researched, regulated, funded and ultimately delivered to patients over the coming decade. Our goal is to create a professional environment where science, clinical practice, investment and policy can come together to support better mental health outcomes.”
Beyond its healthcare and research focus, the symposium is expected to contribute to Melbourne’s visitor economy through interstate and international visitation, hotel accommodation, hospitality spending and associated business tourism activity.
The event is supported by Psychedelics.Media, a new global industry news and broadcasting service covering developments in psychedelic medicine, mental health innovation, clinical research, healthcare policy and emerging companies operating across the sector.








